Cecilia J. Hillard, PhD
Associate Dean for Research; Professor; Director, Neuroscience Research Center
- Pharmacology and Toxicology
BS, Chemistry, University of Virginia, 1977
Dr. Hillard was named Associate Dean for Research in November 2015 after serving eight months as co-Interim Senior Associate Dean for Research. She has served as director of the Neuroscience Research Center since its inception in 2010. She was also Inaugural Director of the Neuroscience Graduate Training Program from 1996-2010. As a highly active researcher, Dr. Hillard’s laboratory is primarily focused on the pharmacology and biochemistry of the cannabinoids and endocannabinoids. Her significant bibliography and frequent invitations to present attest to her reputation as a leader in her field. Dr. Hillard is an MCW graduate and a true advocate for the Basic Sciences. Frequently named an Outstanding Medical Student Teacher, Dr. Hillard takes an active role in training and mentorship, receiving MCW’s highest honor, the Distinguished Service Award, in 2011.
Dr. Hillard was recently awarded the Lifetime Achievement Award from the International Cannabinoid Research Society. Dr. Hillard is a member of both the Society of Teaching Scholars and the Society for Research Excellence at MCW.
- Cannabinoid Receptor Agonists
- Cannabinoid Receptor Modulators
- Carrier Proteins
- Cells, Cultured
Marijuana has been used by humans for more than 2,500 years as a medicinal agent and social drug. Cannabinoids are the chemicals in marijuana that are responsible for its effects on the body. A long-standing interest of our laboratory is the study of the mechanisms by which the cannabinoids affect the function of the brain. Delta-9-tetrahydrocannabinol (THC) is the cannabinoid in marijuana that is responsible for its mood- and sensation-altering effects. THC targets two receptors: the CB1 receptor present on neurons and the CB2 receptor that is present primarily on immune cells. Although THC targets these receptors when a person is exposed to the drug from the outside, we know that at least two “endogenous” (or, from the self) molecules also target these receptors. These two molecules are named the endocannabinoids. Our research focuses on the cannabinoids, the receptors with which they interact and the role of the endocannabinoids in brain function.
We have three major research projects:
Studies of the biochemical mechanisms involved in the synthesis, release and degradation of the endocannabinoids
At least two lipid molecules are thought to act as endocannabinoids, anandamide and 2-arachidonoylglycerol. Both can be synthesized by neurons but our knowledge of the mechanisms that regulate their synthesis is lacking in detail. One goal of our work is to develop inhibitors of these pathways to help us understand the physiological roles of endocannabinoids. We are also studying the processes by which the endocannabinoids are inactivated. We know that they are catabolized by enzymes and that they are substrates for transporters that act in plasma membranes. One of our goals is to biochemically understand these processes and to develop inhibitors.
Studies of the role of endocannabinoid signaling in the regulation of mood and responses to stress
Several laboratories, including ours, have demonstrated that one very important function of the endocannabinoids is to regulate the response of the brain to stress. Animals and humans need to cope with physical and psychological stresses in order to survive, but stress responses have a cost. For example, we know that long term stress exposure results in depression and post traumatic stress disorder in humans. The endogenous cannabinoid system is a stress buffer, it turns down the hormonal and behavioral responses to stress. In addition, the endocannabinoid system is itself turned on or, in some cases, turned off by stress. Our goal in these studies is to examine the mechanistic relationships between stress and the endocannabinoids. While most of our studies are carried out using rodent models, we are also exploring these processes in human subjects exposed to periods of psychological stress through collaborations with other investigators.
Roles of cannabinoids in regulation of the immune response
Signaling through the CB2 receptor has been shown to reduce activation of the immune system. Although immune cell activation is vital to fight infections, excess or inappropriate immune activation contributes to many important and devastating diseases, including multiple sclerosis and graft-versus-host disease, which can occur after bone marrow transplants to treat cancer. Our laboratory is exploring the roles of CB2 receptors and the phytocannabinoid, cannabidiol, in neuroinflammation and graft-versus-host disease models.
(Venkatesan T, Hillard CJ, Rein L, Banerjee A, Lisdahl K.) Clin Gastroenterol Hepatol. 2020 May;18(5):1082-1090.e2 PMID: 31352091 SCOPUS ID: 2-s2.0-85081912688 07/29/2019
(Doncheck EM, Liddiard GT, Konrath CD, Liu X, Yu L, Urbanik LA, Herbst MR, DeBaker MC, Raddatz N, Van Newenhizen EC, Mathy J, Gilmartin MR, Liu QS, Hillard CJ, Mantsch JR.) Neuropsychopharmacology. 2020 Apr 17 PMID: 32303052 SCOPUS ID: 2-s2.0-85084141235 04/18/2020
(Ke X, Fu Q, Sterrett J, Hillard CJ, Lane RH, Majnik A.) Physiol Rep. 2020 Apr;8(8):e14407 PMID: 32333646 PMCID: PMC7183239 SCOPUS ID: 2-s2.0-85084031438 04/26/2020
(Hanlon EC, Leproult R, Stuhr KL, Doncheck EM, Hillard CJ, Van Cauter E.) J Clin Endocrinol Metab. 2020 Mar 01;105(3) PMID: 31970413 PMCID: PMC7015463 SCOPUS ID: 2-s2.0-85079347809 01/24/2020
(Yasmin F, Colangeli R, Morena M, Filipski S, van der Stelt M, Pittman QJ, Hillard CJ, Teskey GC, McEwen BS, Hill MN, Chattarji S.) Proc Natl Acad Sci U S A. 2020 01 07;117(1):650-655 PMID: 31843894 PMCID: PMC6955336 SCOPUS ID: 2-s2.0-85077654645 12/18/2019
(Brellenthin AG, Crombie KM, Hillard CJ, Brown RT, Koltyn KF.) Subst Abus. 2019 Nov 15:1-12 PMID: 31729933 PMCID: PMC7225058 11/16/2019
(Meyer JD, Crombie KM, Cook DB, Hillard CJ, Koltyn KF.) Med Sci Sports Exerc. 2019 09;51(9):1909-1917 PMID: 30973483 PMCID: PMC6727944 SCOPUS ID: 2-s2.0-85070841260 04/12/2019
(Crombie KM, Leitzelar BN, Brellenthin AG, Hillard CJ, Koltyn KF.) Biol Psychol. 2019 07;145:1-7 PMID: 30978371 SCOPUS ID: 2-s2.0-85064154072 04/13/2019
(Murataeva N, Miller S, Dhopeshwarkar A, Leishman E, Daily L, Taylor X, Morton B, Lashmet M, Bradshaw H, Hillard CJ, Romero J, Straiker A.) Exp Eye Res. 2019 05;182:74-84 PMID: 30905716 PMCID: PMC6504573 SCOPUS ID: 2-s2.0-85063275776 03/25/2019
(Bhandari S, Jha P, Lisdahl KM, Hillard CJ, Venkatesan T.) Intern Med J. 2019 05;49(5):649-655 PMID: 30426628 SCOPUS ID: 2-s2.0-85065707659 11/15/2018
(Hill MN, Eiland L, Lee TTY, Hillard CJ, McEwen BS.) Neuropharmacology. 2019 03 01;146:154-162 PMID: 30496752 PMCID: PMC6347425 SCOPUS ID: 2-s2.0-85057629348 11/30/2018
(Borowska-Fielding J, Murataeva N, Smith B, Szczesniak AM, Leishman E, Daily L, Toguri JT, Hillard CJ, Romero J, Bradshaw H, Kelly MEM, Straiker A.) Neuropharmacology. 2018 10;141:21-31 PMID: 30121200 PMCID: PMC6314309 SCOPUS ID: 2-s2.0-85053042908 08/20/2018